Patents by Inventor Amiram Goldblum

Amiram Goldblum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240261296
    Abstract: The present invention provides compositions and methods for preserving pancreatic ?-cell populations and for the treatment of diabetes. In particular, embodiments of the invention relate to the use of newly identified prostaglandin receptor 3 (EP3) antagonists that are exceptionally effective in enhancing the viability and/or activity of pancreatic P cells.
    Type: Application
    Filed: April 6, 2022
    Publication date: August 8, 2024
    Applicants: Hadasit Medical Research Serices & Development Ltd., Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
    Inventors: Danielle Melloul, Amiram Goldblum
  • Patent number: 11771702
    Abstract: Disclosed are PPAR receptor modulators and their uses in medicine. The novel agonists for PPAR-? were found by screening molecules through a chemoinformatics-based model. The novel agonists for PPAR-? are proposed for use in medicine.
    Type: Grant
    Filed: November 28, 2019
    Date of Patent: October 3, 2023
    Inventor: Amiram Goldblum
  • Publication number: 20230172929
    Abstract: The technology disclosed herein concerns compounds capable of binding to CB1Rs in the periphery and not in the CNS.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 8, 2023
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Joseph TAM, Amiram GOLDBLUM, Shayma EL-ATAWNEH, Shira HIRSH
  • Publication number: 20230129331
    Abstract: The present disclosure provides liposomal formulations comprising a lipid membrane comprising at least one liposome forming phospholipid and a sterol; and an intraliposomal aqueous compartment encapsulating at least one ATI receptor blocker (ARB) and a pH-dependent ionizable anion; with the liposomes having an effect upon administration to a subject in need of said effect, without causing a reduction in mean blood pressure of said subject of more than 50% as compared to the administration of the same amount of ARB in free form. The liposomes can be for systemic administration, e.g. by injection or for pulmonary administration, e.g.
    Type: Application
    Filed: March 25, 2021
    Publication date: April 27, 2023
    Inventors: Yechezkel Barenholz, Ahuva Cern, Amiram Goldblum
  • Publication number: 20220023308
    Abstract: Provided is based on the discovery of novel agonists for PPAR-? which are proposed for use in medicine.
    Type: Application
    Filed: November 28, 2019
    Publication date: January 27, 2022
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Amiram GOLDBLUM, Jianwei CHE, Anwar RAYAN, Binyamin DAADOOSH, David MARCUS
  • Patent number: 10004688
    Abstract: Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: June 26, 2018
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel Barenholz, Amiram Goldblum, Ahuva Cern
  • Publication number: 20170027869
    Abstract: Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.
    Type: Application
    Filed: April 8, 2015
    Publication date: February 2, 2017
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Yechezkel BARENHOLZ, Amiram GOLDBLUM, Ahuva CERN
  • Publication number: 20070156343
    Abstract: A stochastic algorithm has been developed for predicting the drug-likeness of molecules. It is based on optimization of ranges for a set of descriptors. Lipinski's “rule-of-5”, which takes into account molecular weight, logP, and the number of hydrogen bond donor and acceptor groups for determining bioavailability, was previously unable to distinguish between drugs and non-drugs with its original set of ranges. The present invention demonstrates the predictive power of the stochastic approach to differentiate between drugs and non-drugs using only the same four descriptors of Lipinski, but modifying their ranges. However, there are better sets of 4 descriptors to differentiate between drugs and non-drugs, as many other sets of descriptors were obtained by the stochastic algorithm with more predictive power to differentiate between databases (drugs and non-drugs). A set of optimized ranges constitutes a “filter”.
    Type: Application
    Filed: October 24, 2006
    Publication date: July 5, 2007
    Inventors: Anwar Rayan, Amiram Goldblum